Association between socioepidemiological variables and COVID-19 vaccine response
DOI:
https://doi.org/10.18378/rebes.v15i3.11574Keywords:
Epidemiology, COVID-19, VaccinationAbstract
The objective of this study was to analyze the relationship between socioepidemiological variables and COVID-19 vaccination response. This ecological study sought data available in the municipal observatory's public epidemiological database. Data were collected using a domain-specific instrument. The search in these public databases ran from January to March 2023, with a time frame from 2022 to April 2023, resulting in a sample of 404 people. The data were analyzed using descriptive and inferential statistics, with a significance level of 5%. The data reveal that patients up to 40 years of age were 1.80 times more likely to experience a vaccine reaction compared to individuals over 40. Furthermore, the analysis reveals that the vaccine provides greater protection against adverse reactions, with a 3.19 times greater chance of developing these symptoms. The findings of this study indicate that the vaccine response to COVID-19 presents significant variations according to socioepidemiological characteristics and reinforce the importance of considering individual and sociodemographic aspects in the evaluation and planning of immunization strategies over time.
Downloads
References
BARTSCH, S. M. et al. Vaccineefficacyneeded for a COVID-19 coronavirusvaccinetopreventor stop anepidemic as the sole intervention. American JournalofPreventiveMedicine , v. 59, n. 4, p. 493–503, 2020.10.1016/j.amepre.2020.06.011
BRASIL. Ministério da Saúde.Boletim Epidemiológico nº 153 - Boletim COE Coronavírus. Brasília, 2023. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/covid-19/2023/boletim_covid_153_julho_11set23.pdf/view. Acesso em: 1 ago. 2024.
CAI, C. et al. A comprehensiveanalysisoftheefficacyandsafetyof COVID-19 vaccines. Molecular Therapy, v. 29, n. 9, p. 2794–2805, 2021. 10.1016/j.ymthe.2021.08.001
CHE, Y. et al. Randomized, double-blinded, placebo-controlledphase 2 trialofaninactivatedSevereAcuteRespiratorySyndromeCoronavirus 2 vaccine in healthyadults. ClinicalInfectiousDiseases, v. 73, n. 11, p. e3949–e3955, 2021.10.1093/cid/ciaa1703
CHEN, M. et al. Safetyof SARS-CoV-2 vaccines: a systematicreviewand meta-analysisofrandomizedcontrolledtrials. InfectiousDiseasesofPoverty, v. 10, n. 1, p. 94, 2021. 10.1093/cid/ciaa1703
CUCINOTTA, D.; VANELLI, M. WHO declares COVID-19 a pandemic. ActaBiomedica, v. 91, n. 1, p. 157–160, 2020. 10.23750/abm.v91i1.9397
FOLEGATTI, P. M. et al. Safetyandimmunogenicityofthe ChAdOx1 nCoV-19 vaccineagainst SARS-CoV-2: a preliminaryreportof a phase 1/2, single-blind, randomisedcontrolledtrial. The Lancet, v. 396, n. 10249, p. 467–478, 2020. 10.1016/S0140-6736(20)31604-4
GRIECO, T. et al. Cutaneous adverse reactionsafter COVID-19 vaccines in a cohortof 2740 Italiansubjects: anobservationalstudy. DermatologicTherapy, v. 34, n. 6, e15153, 2021. 10.1111/dth.15153
HAYNES, B. F. et al. Prospects for a safe COVID-19 vaccine. Science Translational Medicine, v. 12, n. 568, eabe0948, 2020. 10.1126/scitranslmed.abe0948
JOHNS HOPKINS CORONAVIRUS RESOURCE CENTER. JohnsHopkins CoronavirusResource Center. Disponívelem: https://coronavirus.jhu.edu/vaccines/international. Acessoem: 14 jun. 2023.
JOHNS HOPKINS UNIVERSITY.Mortalityanalyses. Johns Hopkins CoronavirusResource Center, 2022. Disponívelem: https://coronavirus.jhu.edu/data/mortality. Acessoem: 20 abr. 2023.
KOUHPAYEH, H. et al. Adverse eventsfollowing COVID-19 vaccination: a systematicreviewand meta-analysis. InternationalImmunopharmacology, v. 109, p. 108906, 2022. 10.1016/j.intimp.2022.108906
MCMAHON, D. E. et al. Cutaneousreactionsreportedafter Moderna and Pfizer COVID-19 vaccination: a registry-basedstudyof 414 cases. JournaloftheAmerican AcademyofDermatology, v. 85, n. 1, p. 46–55, 2021. 10.1016/j.jaad.2021.03.092
MOORE, D. C. B. et al. Low COVID-19 vaccinehesitancy in Brazil. Vaccine, v. 39, n. 42, p. 6262–6268, 2021. 10.1016/j.vaccine.2021.09.013
NASCIMENTO, A. C. M. et al. COVID-19 riskareasassociatedwith social vulnerability in northeasternBrazil: anecologicalstudy in 2020. JournalofInfection in Developing Countries, v. 16, n. 8, p. 1285–1293, 2022. 10.3855/jidc.15214
PEREIRA, F. A. C. et al. Profile of COVID-19 in Brazil—Riskfactorsandsocioeconomicvulnerabilityassociatedwithdiseaseoutcome: retrospectiveanalysisofpopulation-basedregisters. BMJ Global Health, v. 7, n. 12, e009489, 2022. 10.1136/bmjgh-2022-009489
POLACK, F. P. et al. Safetyandefficacyofthe BNT162b2 mRNA Covid-19 vaccine. The New EnglandJournalof Medicine, v. 383, n. 27, p. 2603–2615, 2020. 10.1056/NEJMoa2034577
SHEARN, C.; KROCKOW, E. M. Reasons for COVID-19 vaccinehesitancy in ethnicminoritygroups: a systematicreviewandthematicsynthesisofinitialattitudes in qualitativeresearch. SSM –QualitativeResearch in Health, v. 3, p. 100210, 2023. 10.1016/j.ssmqr.2022.100210
SILVEIRA, M. M.; CONRAD, N. L.; LEITE, F. P. L. Effectof COVID-19 onvaccinationcoverage in Brazil. Journalof Medical Microbiology, v. 70, n. 11, 2021. 10.1099/jmm.0.001466
VOYSEY, M. et al. Safetyandefficacyofthe ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysisof four randomisedcontrolledtrials in Brazil, South Africa, andthe UK. The Lancet, v. 397, n. 10269, p. 99–111, 2021. 10.1016/S0140-6736(20)32661-1
WALSH, E. E. et al. Safetyandimmunogenicityoftwo RNA-based Covid-19 vaccine candidates. The New EnglandJournalof Medicine, v. 383, n. 25, p. 2439–2450, 2020. 10.1056/NEJMoa2027906
WATSON, O. J. et al. Global impactofthefirstyearof COVID-19 vaccination: a mathematicalmodellingstudy. The Lancet InfectiousDiseases, v. 22, n. 9, p. 1293–1302, 2022. 10.1016/S1473-3099(22)00320-6
WESCHAWALIT, S. et al. Cutaneous adverse eventsafter COVID-19 vaccination. Clinical, CosmeticandInvestigationalDermatology, v. 16, p. 1161–1170, 2023. 10.2147/CCID.S410690
WU, Z. et al. Safety, tolerability, andimmunogenicityofaninactivated SARS-CoV-2 vaccine (CoronaVac) in healthyadultsaged 60 yearsandolder: a randomised, double-blind, placebo-controlled, phase 1/2 clinicaltrial. The Lancet InfectiousDiseases, v. 21, n. 6, p. 803–812, 2021. 10.1016/S1473-3099(20)30987-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Vinicius Lino de Souza Neto, Gabriel Ferreira Calixto , Emilly Lima de Castro, Micaely Pereira Sousa, Heloíse Rodrigues Alves de Sá, Isabele Santos Silva Razoni, Albertina Loren Braz Nascimento, Stephane Berredo Matos Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Termo de cess
1.png)
+55 83 988784633 (Milena Sousa)
